PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk

Abstract

Listen

Translate article

Introduction: Abnormal blood cholesterol levels in patients with increased cardiovascular risk have a worse prognosis for patient survival. Treating dyslipidemia is important because it can improve patient comfort and safety. It sometimes happens that currently used drugs to lower cholesterol are not effective - patients develop tolerance or experience serious side effects. For this reason, scientists are looking for new drugs with a different mechanism of action. An example of such a group of drugs are PCSK9 inhibitors used to treat dyslipidemia. In this paper, we will look at the effectiveness of currently used PCSK9 inhibitors, but also at the potential risks associated with their use. Material and methods: We searched for materials for this work in the Pubmed and Google Scholar databases using the keywords: "dyslipidemia", "cardiovascular disease", "PCSK9 inhibitors", "statins". Then we analyzed the selected materials. Aim of the study: Evaluation of the Conclusion: PCSK9 inhibitors are drugs that are very effective in lowering low-density lipoprotein (LDL-C), while reducing cardiovascular risk and potentially having long-lasting effects. Scientists are looking for new PCSK9 inhibitors with different mechanisms of action, which will be an even more effective therapy in lowering LDL-C.